🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Edinburgh
Clinical trial register · United Kingdom · industry-sponsored

Clinical Trials in Edinburgh

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a UK site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full UK registry across all sponsors is far larger. UK studies may also be registered separately on ISRCTN.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 2846 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 19 Sep 2026, 04:26 UTC
2846
Studies in scope
industry-sponsored, all four open statuses
1377
Recruiting now
open to new participants
539
Lead sponsors
across recruiting studies
Top sites
London 99 Manchester 39 Cambridge 26 Glasgow 23 Bristol 17
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca34 Merck Sharp & Dohme LLC15 Janssen Research & Development, LLC13 AbbVie10 Hoffmann-La Roche9 Clear sponsor filter
Site city
London99 Manchester39 Cambridge26 Glasgow23 Bristol17
All 91 cities
Target enrolment
to
15 of 2846 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
UK sites
Start
Recruiting
A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034)
NCT07489495Carcinoma, Renal Cell
Merck Sharp & Dohme LLC
Phase 3
758
Edinburgh, Leicester, Withington, Birmingham
2026-04-09
Recruiting
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
NCT07216703Cervical Cancer
Merck Sharp & Dohme LLC
Phase 3
1,023
Edinburgh, Withington
2026-01-19
Recruiting
A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)
NCT06979596Malignant Neoplasm
Merck Sharp & Dohme LLC
Phase 2
250
East Sussex, Truro, London, Edinburgh, Birmingham, Manchester
2025-08-11
Recruiting
Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03)
NCT07049926Renal Cell Carcinoma
Merck Sharp & Dohme LLC
Phase 1/2
140
Edinburgh, Glasgow, London, Cardiff, Manchester
2025-07-20
Recruiting
A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)
NCT07033494Early Alzheimer's Disease
Merck Sharp & Dohme LLC
Phase 2
340
Aberdeen, Edinburgh, Southampton, London, Oxford, Bath, Birmingham
2025-07-16
Recruiting
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
NCT06952504Endometrial Cancer
Merck Sharp & Dohme LLC
Phase 3
1,123
East Sussex, Cambridge, Glasgow, London, Edinburgh, Leicester, Maidstone, Manchester
2025-05-22
Recruiting
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
NCT06824467Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
Merck Sharp & Dohme LLC
Phase 3
770
Cambridge, Edinburgh, Preston, London, Sutton, Birmingham, Leicester, Liverpool
2025-04-09
Recruiting
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
NCT06393374Triple-Negative Breast Cancer
Merck Sharp & Dohme LLC
Phase 3
1,530
Bristol, Truro, London, Edinburgh, Leeds
2024-06-24
Active, closed
A Study of Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Renal Cell Carcinoma (V940-004).
NCT06307431Renal Cell Carcinoma
Merck Sharp & Dohme LLC
Phase 2
272
Cambridge, Glasgow, London, Edinburgh, Manchester
2024-04-10
Active, closed
A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)
NCT05933577Melanoma
Merck Sharp & Dohme LLC
Phase 3
1,089
Bristol, Cambridge, Cringleford, London, Edinburgh, Oxford, Leeds, Manchester
2023-07-19
Active, closed
Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)
NCT04626518Carcinoma, Renal Cell
Merck Sharp & Dohme LLC
Phase 1/2
370
Southampton, Glasgow, Preston, Leicester, London, Edinburgh, Cardiff, Manchester
2020-12-17
Active, closed
Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)
NCT04626479Carcinoma, Renal Cell
Merck Sharp & Dohme LLC
Phase 1/2
400
Southampton, Glasgow, Preston, Leicester, London, Edinburgh, Cardiff, Manchester
2020-12-16
Active, closed
A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)
NCT04195750Carcinoma, Renal Cell
Merck Sharp & Dohme LLC
Phase 3
755
Cambridge, Edinburgh, Glasgow, London, Sutton, Gillingham, Manchester
2020-02-27
Active, closed
Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Participants Who Are Cisplatin-ineligible or Decline Cisplatin With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303)
NCT03924895Urinary Bladder Cancer, Muscle-invasive
Merck Sharp & Dohme LLC
Phase 3
595
Walsall, Canterbury, Middlesbrough, London, Stevenage, Edinburgh, Metropolitan Borough of Wirral, Truro
2019-07-24
Recruiting
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
NCT03486873Solid Tumors, Hematologic Malignancies
Merck Sharp & Dohme LLC
Phase 3
3,500
Aberdeen, Cambridge, Edinburgh, Manchester, Sheffield, Broomfield, Glasgow, Preston
2018-08-21
Rows per page Showing 1–15 of 15
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a UK investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 19 September 2026. https://priyalifescience.com/clinical-trials-uk/city/edinburgh

Query this register directly
GET /api/trials?country=uk&status=recruiting&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the UK Pharma Salary Guide, or see the Ireland, EU and USA registers.